2023 HCPCS Code C9081

Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Notice HCPCS C9081 terminated on December 31, 2021.
Short Description Idecabtagene car pos t
HCPCS Coverage Code D = Special coverage instructions apply
HCPCS Action Code N = No maintenance for this code
HCPCS Action Effective Date January 01, 2022
HCPCS Code Added Date October 01, 2021
HCPCS Termination Date December 31, 2021
HCPCS Pricing Indicator Code 53 = Statute
HCPCS Multiple Pricing Indicator Code A = Not applicable as HCPCS priced under one methodology
HCPCS Statute Number 1833(t)
HCPCS Cross Reference Code Q2055
HCPCS Type Of Service Code 9 = Other medical items or services
F = Ambulatory surgical center (facility usage for surgical services)
HCPCS Anesthesia Base Unit Quantity 0